Skip to main content
Erschienen in: Investigational New Drugs 5/2011

01.10.2011 | SHORT REPORT

Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer

verfasst von: Achillia Lakka, Ilias Mylonis, Sophia Bonanou, George Simos, Andreas Tsakalof

Erschienen in: Investigational New Drugs | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Summary

Hypoxia-Inducible Factor 1 (HIF-1), a transcriptional activator, is highly involved in the pathology of cancer. Inhibition of HIF-1 retards tumor growth and enhances treatment efficiency when used in combination with chemo- or radiation therapy. The recent validation of HIF-1 as an important drug target in cancer treatment has stimulated efforts to identify and isolate natural or synthetic HIF-1 inhibitors. In the present study, quercetin, a known inhibitor of HIF-1, was imprinted in a polymer matrix in order to prepare a Molecularly Imprinted Polymer (MIP), which was subsequently used for the selective isolation of new inhibitors from frankincense, a gum resin used as anticancer remedy in traditional medicine. The frankincense components isolated by Solid Phase Extraction on MIP (MIP-SPE), efficiently inhibited the transcriptional activity of HIF-1 and decreased the protein levels of HIF-1α, the regulated subunit of HIF-1. The selective retention of acetyl 11-ketoboswellic acid (AKBA, one of the main bioactive components of frankincense) by MIP led to the revealing of its inhibitory activity on the HIF-1 signaling pathway. AKBA was selectively retained by SPE on the quercetin imprinted polymer, with an imprinting effect of 8.1 ± 4.6. Overall, this study demonstrates the potential of MIP application in the screening, recognition and isolation of new bioactive compounds that aim selected molecular targets, a potential that has been poorly appreciated until.
Literatur
1.
Zurück zum Zitat Semenza GL (2000) HIF-1 and human disease: one highly involved factor. Genes Dev 14(16):1983–1991PubMed Semenza GL (2000) HIF-1 and human disease: one highly involved factor. Genes Dev 14(16):1983–1991PubMed
2.
Zurück zum Zitat Park JW, Chun YS, Kim MS (2004) Hypoxia-inducible factor 1-related diseases and prospective therapeutic tools. J Pharmacol Sci 94(3):221–232PubMedCrossRef Park JW, Chun YS, Kim MS (2004) Hypoxia-inducible factor 1-related diseases and prospective therapeutic tools. J Pharmacol Sci 94(3):221–232PubMedCrossRef
3.
Zurück zum Zitat Wenger RH (2002) Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 16(10):1151–1162PubMedCrossRef Wenger RH (2002) Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 16(10):1151–1162PubMedCrossRef
4.
Zurück zum Zitat Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12(19–20):853–859PubMedCrossRef Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12(19–20):853–859PubMedCrossRef
5.
Zurück zum Zitat Giaccia A, Siim BG, Johnson RS (2003) HIF-1 as a target for drug development. Nat Rev Drug Discov 2(10):803–811PubMedCrossRef Giaccia A, Siim BG, Johnson RS (2003) HIF-1 as a target for drug development. Nat Rev Drug Discov 2(10):803–811PubMedCrossRef
6.
7.
Zurück zum Zitat Belozerov VE, Van Meir EG (2005) Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 16(9):901–909PubMedCrossRef Belozerov VE, Van Meir EG (2005) Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 16(9):901–909PubMedCrossRef
8.
Zurück zum Zitat Semenza GL (2008) Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60(9):591–597PubMedCrossRef Semenza GL (2008) Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60(9):591–597PubMedCrossRef
9.
Zurück zum Zitat Nagle DG, Zhou YD (2006) Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Curr Drug Targets 7(3):355–369PubMedCrossRef Nagle DG, Zhou YD (2006) Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Curr Drug Targets 7(3):355–369PubMedCrossRef
10.
Zurück zum Zitat Triantafyllou A, Mylonis I, Simos G et al (2008) Flavonoids induce HIF-1alpha but impair its nuclear accumulation and activity. Free Radic Biol Med 44(4):657–670PubMedCrossRef Triantafyllou A, Mylonis I, Simos G et al (2008) Flavonoids induce HIF-1alpha but impair its nuclear accumulation and activity. Free Radic Biol Med 44(4):657–670PubMedCrossRef
11.
Zurück zum Zitat Kong D, Park EJ, Stephen AG et al (2005) Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 65(19):9047–9055PubMedCrossRef Kong D, Park EJ, Stephen AG et al (2005) Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 65(19):9047–9055PubMedCrossRef
12.
Zurück zum Zitat Olenyuk BZ, Zhang GJ, Klco JM et al (2004) Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A 101(48):16768–16773PubMedCrossRef Olenyuk BZ, Zhang GJ, Klco JM et al (2004) Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A 101(48):16768–16773PubMedCrossRef
13.
Zurück zum Zitat Kung AL, Zabludoff SD, France DS et al (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6(1):33–43PubMedCrossRef Kung AL, Zabludoff SD, France DS et al (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6(1):33–43PubMedCrossRef
14.
Zurück zum Zitat Melillo G (2006) Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4(9):601–605PubMedCrossRef Melillo G (2006) Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4(9):601–605PubMedCrossRef
15.
Zurück zum Zitat Mabjeesh NJ, Post DE, Willard MT et al (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62(9):2478–2482PubMed Mabjeesh NJ, Post DE, Willard MT et al (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62(9):2478–2482PubMed
16.
Zurück zum Zitat Semenza GL (2007) Hypoxia-inducible factor 1 (HIF-1) pathway. Science’s STKE 2007 (407):cm8 Semenza GL (2007) Hypoxia-inducible factor 1 (HIF-1) pathway. Science’s STKE 2007 (407):cm8
17.
Zurück zum Zitat Brian S, Blagg J, Kerr TD (2006) Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med Res Rev 26(3):310–338CrossRef Brian S, Blagg J, Kerr TD (2006) Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med Res Rev 26(3):310–338CrossRef
18.
Zurück zum Zitat Aggarwal BB, Sethi G, Baladandayuthapani V et al (2007) Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem 102(3):580–592PubMedCrossRef Aggarwal BB, Sethi G, Baladandayuthapani V et al (2007) Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem 102(3):580–592PubMedCrossRef
19.
Zurück zum Zitat Rapisarda A, Uranchimeg B, Scudiero DA et al (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62(15):4316–4324PubMed Rapisarda A, Uranchimeg B, Scudiero DA et al (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62(15):4316–4324PubMed
20.
Zurück zum Zitat Dai J, Liu Y, Jia H et al (2007) Benzochromenones from the marine crinoid Comantheria rotula inhibit Hypoxia-Inducible Factor-1 (HIF-1) in cell-based reporter assays and differentially suppress the growth of certain tumor cell lines. J Nat Prod 70(9):1462–1466PubMedCrossRef Dai J, Liu Y, Jia H et al (2007) Benzochromenones from the marine crinoid Comantheria rotula inhibit Hypoxia-Inducible Factor-1 (HIF-1) in cell-based reporter assays and differentially suppress the growth of certain tumor cell lines. J Nat Prod 70(9):1462–1466PubMedCrossRef
21.
Zurück zum Zitat Dai J, Fishback JA, Zhou YD et al (2006) Sodwanone and yardenone triterpenes from a South African species of the marine sponge Axinella inhibit hypoxia-inducible factor-1 (HIF-1) activation in both breast and prostate tumor cells. J Nat Prod 69(12):1715–1720PubMedCrossRef Dai J, Fishback JA, Zhou YD et al (2006) Sodwanone and yardenone triterpenes from a South African species of the marine sponge Axinella inhibit hypoxia-inducible factor-1 (HIF-1) activation in both breast and prostate tumor cells. J Nat Prod 69(12):1715–1720PubMedCrossRef
22.
Zurück zum Zitat Mohammed KA, Hossain CF, Zhang L et al (2004) Laurenditerpenol, a new diterpene from the tropical marine alga Laurencia intricata that potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells. J Nat Prod 67(12):2002–2007PubMedCrossRef Mohammed KA, Hossain CF, Zhang L et al (2004) Laurenditerpenol, a new diterpene from the tropical marine alga Laurencia intricata that potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells. J Nat Prod 67(12):2002–2007PubMedCrossRef
23.
Zurück zum Zitat Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4(3):206–220PubMedCrossRef Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4(3):206–220PubMedCrossRef
24.
Zurück zum Zitat Ortholand J-Y, Ganesan A (2004) Natural products and combinatorial chemistry: back to the future. Curr Opin Chem Biol 8(3):271–280PubMedCrossRef Ortholand J-Y, Ganesan A (2004) Natural products and combinatorial chemistry: back to the future. Curr Opin Chem Biol 8(3):271–280PubMedCrossRef
25.
Zurück zum Zitat Koehn FE (2008) High impact technologies for natural products screening. Prog Drug Res 65:176–210 Koehn FE (2008) High impact technologies for natural products screening. Prog Drug Res 65:176–210
26.
Zurück zum Zitat Rathbone DL (2005) Molecularly imprinted polymers in the drug discovery process. Adv Drug Deliv Rev 57(12):1854–1874PubMedCrossRef Rathbone DL (2005) Molecularly imprinted polymers in the drug discovery process. Adv Drug Deliv Rev 57(12):1854–1874PubMedCrossRef
27.
Zurück zum Zitat van Nostrum CF (2005) Molecular imprinting: A new tool for drug innovation. Drug Discov Today: Technol 2(1):119–124CrossRef van Nostrum CF (2005) Molecular imprinting: A new tool for drug innovation. Drug Discov Today: Technol 2(1):119–124CrossRef
28.
Zurück zum Zitat Sellergren B (2003) Molecularly imprinted polymers: man-made mimics of antibodies and their applications in analytical chemistry. Elsevier, Amsterdam Sellergren B (2003) Molecularly imprinted polymers: man-made mimics of antibodies and their applications in analytical chemistry. Elsevier, Amsterdam
29.
Zurück zum Zitat Karpozilos A, Pavlidis N (2004) The treatment of cancer in Greek antiquity. Eur J Cancer 40(14):2033–2040PubMedCrossRef Karpozilos A, Pavlidis N (2004) The treatment of cancer in Greek antiquity. Eur J Cancer 40(14):2033–2040PubMedCrossRef
30.
Zurück zum Zitat Takada Y, Ichikawa H, Badmaev V et al (2006) Acetyl-11-keto-β-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-κB and NF-κB-regulated gene expression. J Immunol 176(5):3127–3140PubMed Takada Y, Ichikawa H, Badmaev V et al (2006) Acetyl-11-keto-β-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-κB and NF-κB-regulated gene expression. J Immunol 176(5):3127–3140PubMed
31.
Zurück zum Zitat O’Mahony J, Molinelli A, Nolan K et al (2006) Anatomy of a successful imprint: analysing the recognition mechanisms of a molecularly imprinted polymer for quercetin. Biosens Bioelectron 21(7):1383–1392PubMedCrossRef O’Mahony J, Molinelli A, Nolan K et al (2006) Anatomy of a successful imprint: analysing the recognition mechanisms of a molecularly imprinted polymer for quercetin. Biosens Bioelectron 21(7):1383–1392PubMedCrossRef
32.
Zurück zum Zitat Umpleby RJ 2nd, Baxter SC, Rampey AM et al (2004) Characterization of the heterogeneous binding site affinity distributions in molecularly imprinted polymers. J Chromatogr B Anal Technol Biomed Life Sci 804(1):141–149CrossRef Umpleby RJ 2nd, Baxter SC, Rampey AM et al (2004) Characterization of the heterogeneous binding site affinity distributions in molecularly imprinted polymers. J Chromatogr B Anal Technol Biomed Life Sci 804(1):141–149CrossRef
33.
Zurück zum Zitat Lyberopoulou A, Venieris E, Mylonis I et al (2007) MgcRacGAP interacts with HIF-1alpha and regulates its transcriptional activity. Cell Physiol Biochem 20(6):995–1006PubMedCrossRef Lyberopoulou A, Venieris E, Mylonis I et al (2007) MgcRacGAP interacts with HIF-1alpha and regulates its transcriptional activity. Cell Physiol Biochem 20(6):995–1006PubMedCrossRef
34.
Zurück zum Zitat Mylonis I, Chachami G, Samiotaki M et al (2006) Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 281(44):33095–33106PubMedCrossRef Mylonis I, Chachami G, Samiotaki M et al (2006) Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 281(44):33095–33106PubMedCrossRef
35.
Zurück zum Zitat Kim H, Spivak DA (2003) New insight into modeling non-covalently imprinted polymers. J Am Chem Soc 125(37):11269–11275PubMedCrossRef Kim H, Spivak DA (2003) New insight into modeling non-covalently imprinted polymers. J Am Chem Soc 125(37):11269–11275PubMedCrossRef
36.
Zurück zum Zitat Buchele B, Simmet T (2003) Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by high-performance liquid chromatography and photodiode array detection. J Chromatogr B Anal Technol Biomed Life Sci 795(2):355–362CrossRef Buchele B, Simmet T (2003) Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by high-performance liquid chromatography and photodiode array detection. J Chromatogr B Anal Technol Biomed Life Sci 795(2):355–362CrossRef
37.
Zurück zum Zitat Banno N, Akihisa T, Yasukawa K et al (2006) Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri. J Ethnopharmacol 107(2):249–253PubMedCrossRef Banno N, Akihisa T, Yasukawa K et al (2006) Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri. J Ethnopharmacol 107(2):249–253PubMedCrossRef
38.
Zurück zum Zitat Manolescu B, Oprea E, Busu C et al (2009) Natural compounds and the hypoxia-inducible factor (HIF) signalling pathway. Biochimie 91(11–12):1347–1358PubMedCrossRef Manolescu B, Oprea E, Busu C et al (2009) Natural compounds and the hypoxia-inducible factor (HIF) signalling pathway. Biochimie 91(11–12):1347–1358PubMedCrossRef
39.
Zurück zum Zitat Triantafyllou A, Liakos P, Tsakalof A et al (2007) The flavonoid quercetin induces hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits cell proliferation by depleting intracellular iron. Free Radic Res 41(3):342–356PubMedCrossRef Triantafyllou A, Liakos P, Tsakalof A et al (2007) The flavonoid quercetin induces hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits cell proliferation by depleting intracellular iron. Free Radic Res 41(3):342–356PubMedCrossRef
40.
Zurück zum Zitat Lee DH, Lee YJ (2008) Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem 105(2):546–553PubMedCrossRef Lee DH, Lee YJ (2008) Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem 105(2):546–553PubMedCrossRef
41.
Zurück zum Zitat Eckert H, Bajorath J (2007) Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. Drug Discov Today 12(5–6):225–233PubMedCrossRef Eckert H, Bajorath J (2007) Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. Drug Discov Today 12(5–6):225–233PubMedCrossRef
42.
Zurück zum Zitat Baringhaus K-H, Hessler G (2004) Fast similarity searching and screening hit analysis. Drug Discov Today: Technol 1(3):197–202CrossRef Baringhaus K-H, Hessler G (2004) Fast similarity searching and screening hit analysis. Drug Discov Today: Technol 1(3):197–202CrossRef
43.
Zurück zum Zitat Plewczynski D, Spieser SA, Koch U (2009) Performance of machine learning methods for ligand-based virtual screening. Comb Chem High Throughput Screen 12(4):358–368PubMedCrossRef Plewczynski D, Spieser SA, Koch U (2009) Performance of machine learning methods for ligand-based virtual screening. Comb Chem High Throughput Screen 12(4):358–368PubMedCrossRef
Metadaten
Titel
Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer
verfasst von
Achillia Lakka
Ilias Mylonis
Sophia Bonanou
George Simos
Andreas Tsakalof
Publikationsdatum
01.10.2011
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 5/2011
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-010-9440-4

Weitere Artikel der Ausgabe 5/2011

Investigational New Drugs 5/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.